DermTech, Inc. (DMTK) News
Filter DMTK News Items
DMTK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest DMTK News From Around the Web
Below are the latest news stories about DERMTECH INC that investors may wish to consider to help them evaluate DMTK as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to dive into the biggest pre-market stock movers for Friday with all the shares investors will want to keep an eye on today! |
DermTech, Inc. (NASDAQ:DMTK) Q3 2023 Earnings Call TranscriptDermTech, Inc. (NASDAQ:DMTK) Q3 2023 Earnings Call Transcript November 2, 2023 DermTech, Inc. beats earnings expectations. Reported EPS is $-0.57, expectations were $-0.68. Operator: Ladies and gentlemen, thank you for standing by. Welcome to DermTech’s Third Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, […] |
DermTech Inc (DMTK) Reports 10% Increase in Total Revenue for Q3 2023ASP for DermTech Melanoma Test Rises by 24% Year-Over-Year |
DermTech Reports Third-Quarter 2023 Financial ResultsSAN DIEGO, November 02, 2023--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its third-quarter 2023 financial results. |
DermTech Announces Release Date for Third-Quarter 2023 Financial ResultsSAN DIEGO, October 12, 2023--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, November 2, 2023 at 5:00 p.m. Eastern Time (ET) to discuss the Company's third-quarter 2023 operating and financial results. In advance of the call on November 2, 2023, DermTech will issue its third-quarter 2023 earnings press release. |
DermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4)SAN DIEGO, September 21, 2023--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that DermTech’s Compensation Committee has granted an equity award to its new chief commercial officer, Mark Aguillard. The award was granted pursuant to the terms of Mr. Aguillard’s employment letter and as a material inducement to his joining the Company as chief commercial officer. |
DermTech Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test (DMT)SAN DIEGO, September 19, 2023--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced agreements with Highmark Inc. (Highmark). The contracts, which are in addition to a favorable coverage policy, enhance access to the foundational assay of the DermTech Melanoma Test (DMT). Highmark and its Blue-branded affiliates provide health insurance to approximately 7 million members in Pennsylvania, Wes |
Insider Sell: DermTech Inc CFO Kevin Sun Sells 9,616 SharesOn September 11, 2023, Kevin Sun, the Chief Financial Officer (CFO) of DermTech Inc (NASDAQ:DMTK), sold 9,616 shares of the company. |
DermTech Appoints Mark Aguillard as Chief Commercial OfficerSAN DIEGO, September 11, 2023--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the appointment of Mark Aguillard as chief commercial officer effective September 19, 2023. Mr. Aguillard will lead DermTech’s overall commercial strategy and execution. |
Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?Here is how DiaMedica Therapeutics, Inc. (DMAC) and DermTech, Inc. (DMTK) have performed compared to their sector so far this year. |